Morning Movers Archives - Page 145 of 3084

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

June 2, 2025

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end...

Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company for $4.65 Million as Part of Company Streamlining

June 2, 2025

LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or...

Goliath Resources Announces Concurrent Non-Brokered Private Placement of Charity Flow-Through Shares Following Previously Announced “Bought Deal” Offering For Combined Gross Proceeds Total Up To C$24,065,200

June 2, 2025

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES...

Global Net Lease Appoints Robert Kauffman as Board Chair

June 2, 2025

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (NYSE: GNL) ("GNL" or the "Company") today announced...

U.S. GoldMining to Join Russell 3000 Index

June 2, 2025

ANCHORAGE, Alaska, June 2, 2025 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to announce...

Cenovus Energy announces redemption of Series 7 Preferred Shares

June 2, 2025

CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (“Cenovus” or the “Company”) (TSX: CVE) (NYSE: CVE) announced...

Radware Expands its Threat Intelligence Services

June 2, 2025

MAHWAH, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions...

BranchOut Food Inc. Announces Plan to Eliminate Current Liability Notes Payable with $1 Million Warrant Exercise and Extension of Key Financing Agreements

June 2, 2025

BEND, Ore., June 02, 2025 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in...

Life360 Proposes Convertible Senior Notes Offering

June 2, 2025

SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- Life360, Inc. (“Life360” or the “Company”) (NASDAQ: LIF, ASX: 360), today announced...

ReGen III Announces Settlement of Debenture Interest with Shares, Sale of Non-Core Asset, and Patents Update

June 2, 2025

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - ReGen III Corp. (TSXV: GIII) (OTCQB: ISRJF) (FSE: PN4) ("ReGen III"...

Immunic to Participate in Investor, Scientific and Industry Conferences in June

June 2, 2025

NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule...

WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30

June 2, 2025

WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto...

Okeanis Eco Tankers Corp. – Ex Dividend Date

June 2, 2025

ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) -- Reference is made to the key information relating to Q1 2025 dividend...

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

June 2, 2025

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and...

WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET

June 2, 2025

WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET Geneva, Switzerland,...

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

June 1, 2025

Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical...

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

June 1, 2025

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription...

Cenovus Energy provides operations update on impact of Alberta wildfires

June 1, 2025

CALGARY, Alberta, June 01, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) is providing an update on its...

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

June 1, 2025

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating...

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

June 1, 2025

PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication...

China Liberal Education Holdings Limited Announces Suspension of Nasdaq Trading

June 1, 2025

BEIJING, June 1, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (Nasdaq: CLEU), a China-based...

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

June 1, 2025

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s...

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that...

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that...

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 31, 2025

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1...

Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...

Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date

May 31, 2025

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)...

Lancaster Resources Announces Closing Conditions Met for Lake Cargelligo Acquisition

May 31, 2025

VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (“Lancaster”), is pleased to...

QYOU Media Reports Q1 FY 2025

May 30, 2025

Adjusted EBITDA Improves 26% Completes Strategic Re-Alignment Forming a Creator Economy and Social Media Marketing-Focused Business Model TORONTO, MUMBAI, India and...

Vecima Announces XGS-PON Solution for Multi-dwelling Units, Integrating Incognito Service Activation Center, Entra® vPON Manager, and Hitron NOVA2208 ONUs

May 30, 2025

VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima Networks Inc. (TSX: VCM) will showcase its new Entra vPON Manager cloud-based XGS-PON platform supporting multi-dwelling...

Quantum eMotion Announces Upsized Brokered LIFE Financing of C$12,000,000

May 30, 2025

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 30, 2025 (GLOBE NEWSWIRE)...

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

May 30, 2025

WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”)...

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing...